Chairman Helge Lund (pictured) and six other directors are stepping down from the company following a dispute with its ...
Michigan lawmakers plan to save money in the state's Medicaid program by limiting the use of popular weight loss drugs to ...
There's growing interest among women to take GLP-1 drugs like semaglutide for weight loss after giving birth and while ...
The wealthy foundation behind Ozempic maker Novo Nordisk has seized control of the company in a boardroom coup after a row ...
Revolutionary progress, like that of GLP-1 drugs, happens when many exceptional people work together, following a robust ...
The current chairman of the Novo Nordisk Foundation, Lars Rebien Sorensen, who served as the pharma's chief executive from ...
After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular ...
Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and ...
Novo Nordisk A/S Chairman Helge Lund is stepping down after a boardroom dispute over governance and will be replaced by Lars Rebien Sorensen, a previous leader of the company who now heads its biggest ...
An April 2025 report from the Initiative for Medicines, Access & Knowledge (I-MAK) presents grossly misleading information ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback